Timor-LesteTuberculosis profile
Population  2015 1.2 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.71–1.8) 100 (60–151)
Mortality (HIV+TB only) <0.01 (0–0.019) 0.32 (0–1.6)
Incidence  (includes HIV+TB) 5.9 (3.8–8.4) 498 (322–712)
Incidence (HIV+TB only) 0.087 (0.053–0.13) 7.3 (4.5–11)
Incidence (MDR/RR-TB)** 0.22 (0.15–0.29) 19 (13–24)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.43 (0.17–0.69) 2.2 (1.1–3.4) 2.7 (1.3–4)
Males 0.49 (0.29–0.69) 2.7 (1.8–3.7) 3.2 (2.1–4.3)
Total 0.92 (0.6–1.2) 5 (3.7–6.3) 5.9 (3.8–8.4)
TB case notifications, 2015  
Total cases notified 3 532
Total new and relapse 3 337
          - % tested with rapid diagnostics at time of diagnosis 25%
          - % with known HIV status 83%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 58%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 57% (40–87)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.21 (0.11–0.37)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 24 <1%
          - on antiretroviral therapy 24 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  120
(110–130)
Estimated % of TB cases with MDR/RR-TB 2.6% (2.3–3) 17% (15–19)  
% notified tested for rifampicin resistance 5% 12% 184
MDR/RR-TB cases tested for resistance to second-line drugs   4
Laboratory-confirmed cases MDR/RR-TB: 4, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 4, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 84% 3 657
Previously treated cases, excluding relapse, registered in 2014 66% 121
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 50% 2
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
35% (33–39)
TB financing, 2016  
National TB budget (US$ millions) 3.8
Funding source: 41% domestic, 59% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data